Hansa Medical’s shares admitted to trading on Nasdaq Stockholm

Important information
The information in this press release is not directed at persons located in
Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea,
Singapore, South Africa, Switzerland, the United States or any other country
where the offer or sale of subscription rights, interim shares or new shares is
not permitted. The information may not be published or distributed, directly or
indirectly, in or into, any of the aforementioned countries or any other country
where such action is wholly or partially subject to legal restrictions or where
such action would require additional prospectuses, other offer documentation,
registrations or other actions in addition to what follows from Swedish law. Nor
may the information be forwarded, reproduced or disclosed in such a manner that
contravenes such restrictions or gives cause to such requirements. Failure to
comply with these instructions may result in a violation of the United States
Securities Act of 1933, as amended (“Securities Act”) or laws applicable in
other jurisdictions.

The information in this press release does not contain or constitute an
invitation or an offer to acquire, sell, subscribe for or otherwise trade in
shares, subscription rights or other securities in Hansa Medical AB. No
subscription rights, interim shares or new shares will be registered under the
Securities Act or in accordance with any other rules or regulations in any other
country than Sweden and may not be transferred or offered for sale in the United
States or any country where such transfer or offer may be prohibited, or to
persons resident in any such country or on account of such persons, other than
pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act or similar legislation in
another country, respectively.

Nasdaq Stockholm’s listing committee has admitted the shares of Hansa Medical AB
(publ) to trading on Nasdaq Stockholm’s main market. The first day of trading is
planned to fall on November 2, 2015.

The resolution to admit Hansa Medical’s shares to trading is conditional upon
the company fulfilling certain formal requirements, inter alia in relation to a
prospectus and education.

The listing on Nasdaq Stockholm’s main market means that Hansa Medical’s listing
on First North Premier ceases. The last trading day in the company’s share on
First North Premier will be October 30, 2015. The company’s shareholders do not
need to take any action because of the listing.

Hansa Medical has applied for approval and registration of a prospectus drafted
due to the listing. It is expected to approved, registered and published on or
around October 26, 2015.

The listing is not combined with any issue, sale or any other offering to the
market.

Fredersen Advokatbyrå AB has acted as legal advisor.

The information in this press release is disclosed pursuant to the Securities
Markets Act or the Financial Instruments Trading Act. The information was
released for public disclosure on October 22, 2015 at 08.00 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-390 85 30
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused
on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading
enzyme in clinical development, with potential use in transplantation and rare
autoimmune diseases. Other projects include HBP (a market introduced diagnostic
marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in
pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's
share (HMED) is listed on First North Premier in Stockholm with Remium Nordic AB
as Certified Adviser.